8-K: Tempest Therapeutics Appoints New Directors and CFO

Tempest Therapeutics has appointed two new independent directors and a new Principal Financial Officer to address board vacancies and leadership transitions.

Summary

• Nicholas Maestas resigned as CFO, effective June 5, 2026.
• Justin Trojanowski, current Corporate Controller and Treasurer, was appointed as Principal Financial Officer effective June 5, 2026.
• Dr. John David Yee and William Drake Richey were appointed as Class II directors effective June 4, 2026.
• The company is actively reconstituting its board and committees to regain compliance with Nasdaq listing rules following a notification of non-compliance on May 22, 2026.
• The company amended its Non-Employee Director Compensation Policy, reducing annual cash retainers for board and committee service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while the board appointments and CFO transition are necessary steps to stabilize governance and Nasdaq compliance, the underlying financial pressure and need for capital remain significant concerns.

Positives

• Strengthened board composition with the addition of two independent directors with extensive financial and medical affairs experience.
• Maintained continuity in the finance department by promoting the existing Corporate Controller to Principal Financial Officer.
• Proactive steps taken to address Nasdaq listing deficiencies regarding board composition.
• Reduction in director cash retainers demonstrates a commitment to disciplined capital allocation.

Negatives

• Departure of the Chief Financial Officer, Nicholas Maestas.
• Recent non-compliance with Nasdaq listing rules due to board vacancies.
• Ongoing need for additional capital to fund operations and maintain status as a going concern.

Risks

• Potential failure to regain full Nasdaq compliance if remaining board vacancies are not filled.
• Significant need for additional capital to fund planned programs and operations.
• Volatility and uncertainty in capital markets for biotechnology companies.
• Risks associated with clinical trial outcomes, including safety or efficacy data that may differ from expectations.
• Potential loss of key personnel beyond the recent CFO resignation.

Future Outlook

The company intends to appoint an additional independent director to complete the reconstitution of the Audit Committee and restore full compliance with Nasdaq requirements. Management remains focused on advancing its CAR-T cell therapy pipeline and maintaining disciplined capital allocation.

Management Comments

• Over the past several months, we have built a portfolio of CAR-T cell therapy product candidates targeting safe, effective treatments for patients with advanced cancers.
• The addition of Drake and John to the Board could further enable us to realize our vision of providing meaningful treatment options to cancer patients that have either failed or relapsed from prior therapies, while supporting Tempests focus on driving growth and disciplined capital allocation.

Industry Context

StockSavvy.ai notes that Tempest Therapeutics is navigating a challenging period common for clinical-stage biotech firms, characterized by the need for board stability to satisfy exchange listing requirements and the constant pressure to manage cash burn while advancing early-stage oncology pipelines.

Comparison to Industry Standards

• The company's board compensation structure, following the reduction in retainers, aligns with lean operational models typical of small-cap clinical-stage biotech companies.
• The reliance on internal promotions for the PFO role is a standard practice in the industry to ensure continuity during executive transitions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Impacted by board stability and the company's ability to maintain Nasdaq listing.
• Creditors: Impacted by the company's ongoing need for capital and going concern status.

Next Steps

• Appoint an additional independent director to restore full Nasdaq compliance.
• File the employment agreement for Justin Trojanowski with the Q2 2026 Form 10-Q.
• File the full text of the Amended Compensation Policy with the Q2 2026 Form 10-Q.

Key Dates

Recommendation

The company is in a transition phase, addressing governance issues and leadership changes while facing significant capital requirements. Investors should wait for further clarity on the clinical pipeline progress and the success of the board reconstitution before increasing exposure.

Keywords

Tempest Therapeutics, TPST, Biotechnology, CAR-T, Corporate Governance, Nasdaq Compliance, Board Appointment, CFO Transition